Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint | WAPE

Newsbenzinga

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

Oct 15, 2026, 08:47 ET · Published

Article summary

Vanda Pharmaceuticals announced its Phase 3 trial for VQW-765 failed to meet primary endpoints for treating acute social anxiety disorder.

An excerpt from the original article.

Related companies

Vanda Pharmaceuticals Inc. Common StockVNDAView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…